<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493570</url>
  </required_header>
  <id_info>
    <org_study_id>1289.3</org_study_id>
    <secondary_id>2011-003749-16</secondary_id>
    <nct_id>NCT01493570</nct_id>
  </id_info>
  <brief_title>Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Due to the exploratory nature of this trial, there is no primary objective in a confirmatory&#xD;
      sense. The study aims&#xD;
&#xD;
      - to evaluate the effect of different doses of BI 409306 on biomarker and to assess the&#xD;
      exposure of BI 409306&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change from baseline (calculated as ratio) of biomarker</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax ratio of BI 409306 in different media</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured biomarker concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum measured in biomarker concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured BI 409306 concentration in different media)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured BI 409306 concentration in different media)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 low dose II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>High dose film-coated tablet</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Low dose film-coated tablet</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Low dose film-coated tablet</description>
    <arm_group_label>BI 409306 low dose II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Medium dose film-coated tablet</description>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Healthy males according to the following criteria:&#xD;
&#xD;
             Based upon a complete medical history, including the physical examination, vital signs&#xD;
             after 10 minutes in supine position (BP (blood pressure), PR (pulse rate), BT (body&#xD;
             temperature)), 12-lead ECG (electrocardiogram), clinical laboratory tests&#xD;
&#xD;
          2. Age =21 and Age =50 years&#xD;
&#xD;
          3. BMI =18.5 and BMI =29.9 kg/m2 (Body Mass Index)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP (Good Clinical Practice) and the local legislation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Any finding of the medical examination (including BP, PR and ECG) deviating from&#xD;
             normal and considered by the investigator as clinical relevant&#xD;
&#xD;
          2. Abnormal values for PT (Prothrombin Time) (, aPTT (Partial Thromboplastin Time) and&#xD;
             trombocytes considered by the investigator as clinically relevant&#xD;
&#xD;
          3. Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          5. Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          6. Diseases of the central nervous system (included but not limited to any kind of&#xD;
             seizures, stroke or psychiatric disorders)&#xD;
&#xD;
          7. History of relevant orthostatic hypotension, fainting spells or blackouts.&#xD;
&#xD;
          8. Chronic or relevant acute infections&#xD;
&#xD;
          9. History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
         10. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration&#xD;
&#xD;
         11. Use of drugs which might reasonably influence the results of the trial or that prolong&#xD;
             the QT/QTc interval based on the knowledge at the time of protocol preparation within&#xD;
             10 days prior to administration or during the trial&#xD;
&#xD;
         12. Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
         13. Smoker, who consume more than 5 cigarettes per day&#xD;
&#xD;
         14. Inability to refrain from smoking on trial days&#xD;
&#xD;
         15. Alcohol abuse (more than 20 g/day): 2 units/day (14 units/week)&#xD;
&#xD;
         16. Drug abuse&#xD;
&#xD;
         17. Blood donation (more than 100 mL within four weeks prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
         18. Excessive physical activities (within one week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
         19. Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
         20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTcF interval &gt;450 ms)&#xD;
&#xD;
         21. Inability to understand and to comply with protocol requirements and restrictions and&#xD;
             dietary regimen of trial site&#xD;
&#xD;
         22. of additional risk factors for TdP (Torsades de points) (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome)&#xD;
&#xD;
         23. Male subjects who do not agree to minimize the risk of female partners becoming&#xD;
             pregnant from the first dosing day until three month after the study completion.&#xD;
             Acceptable methods of contraception comprises barrier contraception and a medically&#xD;
             accepted contraceptive method for the female (intra-uterine device with spermicide,&#xD;
             hormonal contraceptive since at least two months)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.3.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 409306</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

